The data will be submitted to health regulatory bodies as experts believe the trial provides a “great opportunity” to prevent COVID-19 in younger age groups.
A Pfizer-BioNTech COVID-19 vaccine trial for children aged between five and 11 has produced “positive results” and has shown a “robust immune response”, the two firms have said.
They said the results are the first to emerge from any vaccine trial for children aged below 12 and would “provide a strong foundation” for seeking the authorisation of its potential rollout across the world.
Pfizer and BioNTech said the data will be submitted to health regulatory bodies and that they believe the trial provides a “great opportunity” to prevent COVID-19 in younger age groups.
Bill Gruber, the senior vice president of vaccine clinical research and development at Pfizer, told: “This is really great news. We have been able to demonstrate a robust immune response as well as a satisfactory safety profile for the Pfizer-BioNTech COVID-19 vaccine in children five to 11 years of age.
“This is intensive research where we have been very meticulous about defining the best dose that gives us the appropriate level of immune response and reduces as much as possible the common sorts of reactions that we see with vaccines, like fever, a sore arm, maybe headache and sometimes chills.